PNN
Navi Mumbai (Maharashtra) [India], April 25: Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended March 31, 2025. For Q4FY25, the company reported revenue from operations of INR 187.2 crore, reflecting a 21% year-over-year (YoY) growth. Normalized EBITDA for the quarter stood at INR 65.3 crore, marking a robust 78% YoY increase. Profit after tax (PAT), excluding exceptional items, reached INR 32.5 crore, which represents an impressive 88% YoY growth.
Key highlights for Q4FY25:
– Consolidated revenue increased by 21% year-over-year (YoY) with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively
– Total volume in FY25 grew to 167.9 million, largest by far on volume
– Revenue from franchise surged by 22% YoY, and partnership revenue saw 24% YoY growth
– Consolidated gross margin stood at 74%, and normalized EBITDA margin was 35%
– Standalone normalized EBITDA grew by 72% YoY, while PAT* increased by 72% YoY
– Consolidated normalized EBITDA grew by 78% YoY, while PAT* increased by 88% YoY
– Recommended a final dividend of INR 21 per equity share subject to the approval of shareholders at the ensuing shareholders meeting
– Consolidated cash reserves as of March 2025 is INR 191.8 Cr
– Opened new labs in Bhagalpur and Kashmir
* PAT excluding exceptional item of INR 11.2 Cr pertaining to reversal of deferred tax asset created in previous years against the impairment of investment in NHL.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same)
Disclaimer: This story is auto-generated from a syndicated feed of ANI; only the image & headline may have been reworked by News Services Division of World News Network Inc Ltd and Palghar News and Pune News and World News
HINDI, MARATHI, GUJARATI, TAMIL, TELUGU, BENGALI, KANNADA, ORIYA, PUNJABI, URDU, MALAYALAM
For more details and packages
